Share This Page
Patent: 10,316,282
✉ Email this page to a colleague
Summary for Patent: 10,316,282
Title: | Method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process |
Abstract: | A method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. |
Inventor(s): | Laustsen; Mads (Gentofte, DK) |
Assignee: | CMC BIOLOGICS A/S (Soborg, DK) |
Application Number: | 14/778,222 |
Patent Claims: | see list of patent claims |
Patent landscape, scope, and claims summary: | Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 10,316,282 IntroductionPatents are a cornerstone of innovation, providing inventors and companies with the exclusive rights to their creations. To navigate the complex landscape of patent law, it is crucial to understand the various components and processes involved. This article will delve into the specifics of US Patent 10,316,282, analyzing its claims, the broader patent landscape, and the key sections of U.S. patent law that govern its validity. The Patent in Question: US Patent 10,316,282While the specific details of US Patent 10,316,282 are not provided here, a general analysis can be conducted based on common practices and legal frameworks. Patent ClaimsPatent claims are the heart of any patent application, defining the scope of the invention and the rights granted to the patentee. For a patent like 10,316,282, the claims must be carefully crafted to meet the criteria set forth by U.S. patent law.
Strategic Patent DraftingCrafting patent applications with a focus on clarifying the non-obvious aspects of the invention is pivotal. Here are some key strategies:
The Broader Patent LandscapePatent Allowance RatesThe probability of receiving a U.S. patent varies significantly depending on several factors, including the technology field and the type of entity filing the application. Studies have shown that only about 55.8% of patent applications filed at the USPTO are eventually granted without using continuation procedures[1].
The Role of the Patent Trial and Appeal Board (PTAB)The PTAB, established by the Leahy-Smith America Invents Act (AIA) in 2011, plays a crucial role in the patent landscape by providing a mechanism for challenging the validity of patents.
Recent Updates in USPTO Guidance2024 USPTO Guidance Update on AI PatentsThe USPTO has recently updated its guidance on the patent eligibility of AI-related inventions, prompted by Executive Order 14110.
Practical Insights for Patent ApplicantsAligning with Section 101To navigate the nuances of Section 101, innovators should focus on highlighting the tangible and applicable aspects of the invention. Providing clear, concrete embodiments of the invention and explicitly detailing its practical applications can help circumvent issues related to abstract ideas[2]. Effective ArgumentationBuilding compelling arguments around eligibility, novelty, and non-obviousness is crucial. This involves explaining the technological advancements brought about by the invention and distinguishing it clearly from the existing state of the art[2]. Key Takeaways
FAQsWhat is the overall allowance rate for patent applications filed at the USPTO?The overall allowance rate for patent applications filed at the USPTO is approximately 55.8% without using continuation procedures[1]. How does the size of the entity filing the patent application impact the allowance rate?The size of the entity can impact the allowance rate, with small entities (those with 500 or fewer employees) potentially facing different challenges and success rates compared to large entities[1]. What is the role of the Patent Trial and Appeal Board (PTAB) in the patent landscape?The PTAB provides a mechanism for challenging the validity of patents through processes like Inter Partes Review (IPR) and Post-Grant Review (PGR), which are often faster and less expensive than judicial proceedings[4]. How does the 2024 USPTO guidance update impact AI-related patent applications?The update clarifies the patent eligibility of AI-related inventions by focusing on whether the claim integrates a judicial exception into a practical application and ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[5]. What are the key sections of U.S. patent law that govern the validity of a patent?The key sections are Section 101 (patentable subject matter), Section 102 (novelty), and Section 103 (non-obviousness)[2][4]. Sources
More… ↓ |
Details for Patent 10,316,282
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | KOATE, KOATE-DVI | antihemophilic factor (human) | For Injection | 101130 | January 24, 1974 | 10,316,282 | 2033-03-19 |
Takeda Pharmaceuticals U.s.a., Inc. | HEMOFIL M | antihemophilic factor (human) | For Injection | 101448 | March 14, 2001 | 10,316,282 | 2033-03-19 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | 10,316,282 | 2033-03-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |